| By 2025, AbbVie’s industry-leading Humira is expected to sail off the patent cliff and fall to No. 6 in the rankings, while others aim to take its place. That includes Merck’s Keytruda, which GlobalData forecasts will take the crown with $22.5 billion in sales—outpacing not only Bristol-Myers Squibb and Pfizer’s Eliquis and Celgene’s Revlimid, but also BMS’ Opdivo and AbbVie and J&J’s Imbruvica as well. But meanwhile, BMS is working to complete its merger with Celgene, which will give it three of 2025’s top four drugs, totaling over $43 billion. Read on below. | |
|
Featured Story | | | Friday, October 4, 2019 AbbVie's Humira has been topping pharma's sales charts, but in a few years it'll be passed by Merck's Keytruda and several other meds, a GlobalData forecast shows. Also in the top 10 are Bristol and Pfizer's Eliquis, Celgene's Revlimid, and BMS' Opdivo. |
|
|---|
|
Top Stories Of The Week Monday, October 7, 2019 After a series of major exits from its C-suite last year and this year including the exit of Chief Medical Officer Andrew Cheng last fall, Gilead now has a new CMO as it also rejigs its R&D reporting line. Wednesday, October 9, 2019 Merck & Co. and Pfizer are in a very public race to market with their next-gen pneumococcal vaccines. But behind the scenes, Merck claims a former high-level employee jumped ship to Pfizer with a load of trade secrets, giving its rival an unfair advantage. Monday, October 7, 2019 After an unexpected game of executive musical chairs, Akcea Therapeutics has inked a deal with a potential rival. For $250 million upfront, Akcea is licensing an antisense therapy to Pfizer for “certain cardiovascular and metabolic diseases.” Thursday, October 3, 2019 Before Donald Trump became U.S. president, he warned pharma he’d be the one to crack down on the industry. Now, as Democrats advance an impeachment inquiry, he said it wouldn't surprise him if pharma companies were behind the effort. Monday, October 7, 2019 Researchers who advanced understanding of how cells sense and adapt to oxygen availability have won the 2019 Nobel Prize in physiology or medicine. The research could inform development of treatments for diseases including anemia, cancer and stroke. Tuesday, October 8, 2019 Novartis has its next big drug approval. The FDA on Tuesday approved wet AMD drug Beovu, which will go up against entrenched blockbusters Eylea from Regeneron and Lucentis from Roche. The drug has shown it can match up against Eylea's efficacy and bested the Regeneron drug on other measures. Friday, October 4, 2019 Zombie biotech Dynavax will lose its chief scientific officer in December, but after a host of cuts, it won’t be looking for a new one. Friday, October 4, 2019 Physicians are seeing fewer pharma sales reps than ever, which likely isn’t a surprise. But what might raise some eyebrows is the fact that digital contact by reps isn’t taking up the slack. Instead, doctors are searching for drug and treatment information online and on their own. Tuesday, October 8, 2019 Illumina and Qiagen signed on to a long-term diagnostics partnership—with the latter opting to develop kits for the sequencing giant’s hardware, rather than continuing to develop its own instruments. The two companies plan to work together on a series of next-generation sequencing-based tests in different therapeutic areas over the next 15 years. Monday, October 7, 2019 Johnson & Johnson's Janssen has had biopharma operations in Ringaskiddy, Co. Cork for nearly 15 years. Now it has a new $350 million facility there and added 200 jobs. Monday, October 7, 2019 A drug from Boston Pharmaceuticals called BOS172722 causes cancer cells to divide too rapidly and die. The medicine combined with chemo was effective in mouse models of triple-negative breast cancer and is being tested in a phase 1 trial in the U.K. | | [Webinar] CIOs’ Perspectives: Driving Clinical Trial Innovation with a Unified Platform Tuesday, October 15, 2019 | 2pm ET / 11am PT In this webinar, you will hear from Alan Louie , Ph.D, Research Director at IDC , Bill Swavely , CIO at Pharm-Olam, and Rama Kondru , Ph.D, CIO at Medidata about the need for a platform approach in clinical research. Register now. |
Resources Sponsored by: Medidata Simplified filing, improved oversight, audit readiness: is your eTMF system delivering best-in-class benefits? Sponsored by: Colorcon® Learn about how you better manage product authentication and battle drug counterfeiting with innovative solutions. Sponsored by: Cortellis, a Clarivate Analytics Solution Download this report for full details of Life sciences M&As in the second quarter of 2019 with notes and trends. Sponsored by: Elligo Health Research Find out how it leverages real-world data and novel IntElligo Research Stack™ technology to help researchers battle rising costs, cumbersome processes, and stagnant participation — bridging the gap between research and care. Sponsored by: Life Image The time has finally come when medical imaging can be effectively utilized into the RWE process. Read the whitepaper on the best practices for incorporating Real World Imaging.™ Sponsored by: Patheon, by Thermo Fisher Scientific Is your API development on track? Sponsored by: BioAnalytix, Inc. Download the White Paper and learn how detailed characterization can guide successful development of gene therapy products. Sponsored by: ON24 Compare digital program performance and audience engagement among your life sciences peers. Sponsored by: Decision Resources Group Clinically Integrated Networks are vehicles for powerful IDNs to extend their influence into the physician sector and play a key role for IDNs trying to pave a path to becoming a self-contained healthcare ecosystem. Sponsored by: Reprints Desk, Inc. Slashing your R&D costs is easier than you think. Sponsored by: Roche and IQVIA A global landscape study of funding trends and innovations. Sponsored by: Blue Matter, strategic consultants in the life sciences White paper providing an overview of precision medicine in oncology, as well as a look ahead at future developments and keys to success for pharmaceutical and diagnostics companies. Sponsored by: Vineti Developing a cell therapy, gene therapy, or personalized cancer vaccine? Modern data management makes a critical difference in operational and regulatory outcomes. This whitepaper will help your team leverage the latest data strategies for success. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. |
